There are 2789 resources available
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
1054P - FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
Presenter: Florentia Dimitriou
Session: ePoster Display
1055P - Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma
Presenter: Eftychia Chatziioannou
Session: ePoster Display
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Presenter: Ivan Marquez-Rodas
Session: ePoster Display
1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
Presenter: Hucheng Liu
Session: ePoster Display
1058P - Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Presenter: Manon Pillai
Session: ePoster Display
1059P - 18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience
Presenter: Caio De Liz
Session: ePoster Display
1060P - Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1061P - Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme
Presenter: Almudena Garcia Castano
Session: ePoster Display
Resources:
Abstract
1062P - Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands
Presenter: Maartje Rohaan
Session: ePoster Display